Select a medication above to begin.
Yeztugo
lenacapavir
Black Box Warnings .
Drug Resistance Risk in Undiagnosed HIV-1 Infection
test patients for HIV-1 infection prior to starting lenacapavir and w/ each subsequent injection; drug-resistant variants identified in patients w/ undiagnosed HIV-1 infection; do not start lenacapavir unless negative HIV-1 infection status confirmed; patients infected w/ HIV-1 must transition to a complete tx regimen
Adult Dosing .
Dosage forms: TAB: 300 mg; INJ: various
HIV pre-exposure prophylaxis
- [>35 kg]
- Dose: 927 mg SC q6mo; Start: 927 mg SC x1 and 600 mg PO x1 on Day 1, then 600 mg PO x1 on Day 2; Info: may give injection up to 2wk before or after scheduled dose; check HIV status w/ HIV-1 RNA before tx start and w/ every injection or upon diagnosis of other sexually transmitted infections; see pkg insert for missed dose recommendations
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: TAB: 300 mg; INJ: various
HIV pre-exposure prophylaxis
- [adolescents, >35 kg]
- Dose: 927 mg SC q6mo; Start: 927 mg SC x1 and 600 mg PO x1 on Day 1, then 600 mg PO x1 on Day 2; Info: may give injection up to 2wk before or after scheduled dose; check HIV status w/ HIV-1 RNA before tx start and w/ every injection or upon diagnosis of other sexually transmitted infections; see pkg insert for missed dose recommendations
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined